Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
  • C12Q1/701—Specific hybridization probes
  • C12Q1/708—Specific hybridization probes for papilloma
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6813—Hybridisation assays
  • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
  • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2531/00—Reactions of nucleic acids characterised by
  • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
  • C12Q2531/113—PCR

Definitions

• the present invention relates to a nucleic acid primer sequence, a kit, and a nucle'ic acid chain- immobilized carrier for detection of human papilloma virus and identification of its genotype, and a method of detecting human papilloma virus by using a nucleic acid amplification method.
• HPV Human papilloma virus infection was reported as a cause of uterine cervical cancer in the 1980's, and in particular, the relationship between cancer malignancy and HPV genotype is attracting attention. HPV is also considered to be the cause of cancers other than uterine cervical cancer such as cancers of the genital organs and oral mucosa, and there has been a demand for a rapid and accurate method of detecting HPV. Hitherto known were a method of detecting a malignant or benign genotype by using a DNA/RNA- recognizing antibody, and a method of amplifying a region containing a sequence characteristic to a genotype in polymerase chain reaction (PCR) and
• PCR polymerase chain reaction
• the latter method of using the PCR method had disadvantages such as complicated procedure of pretreatment for example nucleic acid extraction, demand for a complex temperature-regulating device such as thermal cycler, and 'longer reaction period of two hours or more.
• the PCR method has a possibility that, if an incorrect
• An object of the present invention is to provide a nucleic acid primer for detection of an HPV nucleotide sequence present in LAMP amplification products when principle of a LAMP method allowing simple and rapid detection of nucleic acids is applied, and an HPV- detection method using the nucleic acid primer.
• the inventions employed a method different from the PCR method, i.e., LAMP method, for identification of the HPV genotype.
• LAMP method a method different from the PCR method, i.e., LAMP method
• the primer is so designed that the human papilloma virus-derived target sequence becomes located in the single-stranded loop region of the LAMP product, differently from before.
• nucleic acid primer for LAMP amplification for use in the detection of human
• nucleic acid primer being selected from the following (a)-(f); (a) a nucleic acid primer containing, on the same chain, a sequence complementary to a sequence selected from those in a first sequence group listed in Table 1 and a sequence selected from those in a second sequence group listed in Table-2; (b) a nucleic acid primer containing, on the same chain, a sequence complementary to a sequence selected from those in the first sequence group and a sequence- selected from those in a third sequence group listed in Table 3; (c) a nucleic acid primer containing, on the same chain, a sequence complementary to a sequence selected from those in the second sequence group and a sequence selected from those in the third sequence group; (d) a nucleic acid primer containing a sequence that differs from a selected sequence of one of the nucleic acid primers (a), (b) , and (c), by insertion, deletion, or substitution of one or more bases, and capable to hybridize with
• a method of detecting human papilloma virus and identifying its genotype comprising a step of amplifying the nucleic acid chains in a sample in LAMP reaction by using multiple primers including at least one primer selected from the nucleic acid primers above and a step of detecting presence of amplified products after the amplification reaction and identifying their genotypes.
• nucleic acid chain- immobilized support carrying an immobilized human papilloma virus- or genotype-specific nucleic acid chain for detection of human-papilloma-virus LAMP amplification products.
• the nucleic acid chain immobilized is (g) a nucleic acid probe
• nucleic acid probe containing a sequence that differs from a selected sequence of one of the nucleic acid probe (g), by insertion, deletion, or substitution of one or more bases, and capable to hybridize with a nucleic acid chain having a sequence complementary to the selected sequence of one of the nucleic acid probe (g) .
• FIG. 1 is a schematic chart showing an
• FIG. 2 is a schematic chart showing amplification products obtained by the conventional LAMP method
• FIG. 3 is a schematic chart showing an
• FIG. 4 is a schematic chart showing nucleic acids for measurement according to the present invention.
• FIG. 5 is a schematic view illustrating an example of a DNA chip for identification of HPV genotype
• FIG. 6 is a schematic view illustrating another example of the DNA chip for identification of HPV genotype
• FIG. 7 is a chart showing an example of
• FIG. 8 is a chart showing another example of the electrophoretic photographs after LAMP amplification
• FIG. 9 includes charts showing examples of results detected by a current-detecting DNA chip
• FIG. 10 include charts showing examples of the electrophoretic photographs after LAMP amplification.
• FIG. 11 is a chart showing an HPV sequence and regions usable as a primer or probe according to the present invention. Best Mode for Carrying Out the Invention
• An amplification method used in the present invention is a kind of isothermal polymerase chain reaction, and- uses 4 or 6 kinds of primers.
• the LAMP method is reported to be higher in amplification efficiency than the PCR method and also resistant to the influence by impurities in a sample. It is thus possible to detect human papilloma virus in a smaller amount easily with simple pretreatment of the sample.
• FIG. 1 shows a double strand DNA to be detected.
• a target sequence has been located in the center of a stem-and- loop structure of LAMP amplification products (FIG. 2).
• FIP primer sequences
• BIP B2 + BIc
• LAMP amplification by using the four kinds of primers gives amplification products with the dumbbell-shaped stem-and-loop structure shown in FIG. 2, each of them being complementary to each strand of the DNA shown in FIG. 1.
• the amplification mechanism is not described here, but may be referred, for example, to in JP-A 2002-186781 (KOKAI) .
• the primers are designed such that the target seguence is placed in the single-stranded loop region, unlike the conventional target-sequence site shown in FIG. 2.
• the target sequence (any one of FPc, FP, BP, and BPc in FIG. 3) is located between primer regions Fl and F2 (including F2 region), between primer regions F2c and FIc (including F2c region), between primer regions Bl and B2 (including B2 region), and/or between primer regions B2c and BIc (including B2c region).
• the target sequence may be placed in any one of the single-stranded loop regions formed between the regions above, and thus, the loop region between primer regions Fl and F2 includes the F2 region.
• a part of LAMP amplification products, which is shown in FIG. 4, are obtained by preparing four kinds of primers according to the six primer regions thus determined and performing LAMP amplification by using these primers. In the LAMP amplification
• target sequences FPc, FP, BP, and BPc are located in the single-stranded loops in the dumbbell structure of the amplification products.
• primer regions FIc and Fl, and Blc and Bl have sequences complementary to each other, and thus, form double strands by selfhybridization .
• SNP polymorphism
• the present invention detects the genotype of HPV virus by applying such a primer structure to HPV virus.
• a sequence shown in FIG. 11 is an HPV virus sequence.
• a region containing SEQ ID Nos . 1, 2 and 3 in the figure is known to be preserved among many HPV viruses.
• the SEQ ID No. 4 shows a region where it is known that there is polymorphism between malignant and benign tumors.
• polymorphism is detected, for example, by using a sequence of the region
• sequences selected from first sequence group (Table 1) and second sequence group (Table 2), or for example sequences selected from first sequence group and third sequence group (Table 3), are used as the sequence corresponding to the primer regions Fl and F2.
• the first, second, and third sequence groups are the sequence groups shown in the following Tables 1 to 3, and respectively correspond to the regions of SEQ ID No. 1, 2, and 3 in FIG. 11.
• the sequence in these regions varies according to its viral type, and is not always identical with the sequence shown in FIG. 11.
• a primer set consisting of BIP and B3 primers is also needed in actual LAMP amplification. It is possible to use the sequences of SEQ ID Nos. 5 and 6 in FIG. 11 or the complementary sequences thereof.
• a primer having, on the same chain in the direction from 5' to 3 ' , a sequence complementary to a sequence selected from those in the first sequence group and a sequence selected from those in the second sequence group bound to each other, a sequence selected from those in the second sequence group and a sequence complementary to a sequence selected from those in the first sequence group bound to each other, a sequence complementary to a sequence selected from those in the first sequence group and a sequence selected from those in the third sequence group bound to each other, a sequence selected from those in the third sequence group and a sequence complementary to a sequence selected from those in the first sequence group bound to each other, a sequence complementary to a sequence selected from' those in the second sequence group and a sequence selected from those in the third sequence group bound to each other, a sequence selected from those in the third sequence group and a sequence complementary to a sequence selected from those in the second sequence group bound to each other, a sequence selected from those in the fourth sequence group (Table 4), or a sequence selected from those in the fourth sequence group (Table 4), or a
• the complementary sequences include strictly complementary sequences and also sequences that ' can hybridize under a condition
• Such a stringent condition would be obvious for those skilled in the art, and is, for example, a temperature in the range of 2O 0 C to 65°C, 2 x SSC buffer solution, and 0.1% w/v SDS. Particularly favorable is a highly stringent condition at a temperature of at least 65°C, 0.1 x SSC buffer solution, and 0.1% w/v SDS.
• the sequence may be sequences of at least one of the strands of SEQ ID Nos. 1, 2 and 3 or the complementary strands thereof that have one or more nucleotides (e.g., 1 to 5 nucleotides) thereof substituted, deleted, or inserted.
• substituted, deleted, or inserted sequences are sequences that can hybridize respectively with the complementary strands of unsubstituted, undeleted, or uninserted sequences under the stringent condition.
• at least one of SEQ ID Nos . 1, 2 and 3 and the complementary strands thereof may be a mixed- nucleotide sequence of 1 to 5 nucleotides, or at least one of SEQ ID Nos. 1, 2 and 3 and the complementary strands thereof may be a sequence of 1 to 5 nucleotides bring a universal nucleotide. Examples of the
• universal nucleotides for use include deoxyinosine (dl), and 3-Nitropyrrole, 5-Nitroindole,
• deoxyribofuranosyl (dP) deoxy-5 ' -dimethoxytrityl-D- ribofuranosyl (dK) available from Gren Research. It would be obvious for those skilled in the art that these primer regions may be bound to each other
• the length of the nucleic acid primer is about 15 to 200 nucleotides, preferably 20 to 100
• nucleotides and more preferably 40 to 60 nucleotides.
• the target sequence FPc, FP, BP, or BPc located in the single-stranded loop of the dumbbell structure of the product amplified with the LAMP primer correspond to the sequence of SEQ ID No. 4.
• HPV-derived target sequence i.e., sequence in the region corresponding to SEQ ID No. 4
• sequence in the region corresponding to SEQ ID No. 4 contained in a single-stranded loop structure of a amplification product having a stem-and-loop structure
• the amplification reaction may be carried out by using one primer set per tube or multiple primer sets for various genotypes per tube. It is more efficient to use the latter method for identification of multiple genotypes at the same time.
• the amplification products are detected, for example, by using probe nucleic acids (FP, FPc, BP, and BPc) having a sequence complementary to the SEQ ID No. 4.
• Homogeneous hybridization is achieved by using nucleic acid probe labeled by such as fluorochrome (Fluorescein, Rhodamine, FITC, FAM, TET, JOE, VIC, MAX, ROX, HEX, TAMRA, Cy3, Cy5, TexasRed, etc.),
• TAMRA quencher
• FRET fluorescence resonance energy transfer
• ESR electron spin resonance
• Homogeneous hybridization assay for LAMP products is not particularly limited.
• the probe nucleic acids may be immobilized on the surface of a solid support for heterogeneous hybridization, and typically, a DNA chip is used, but a probe on another microarray may be used.
• the region of the SEQ ID No. 4 is a polymorphic region, and thus, the probe nucleic acids for detection of amplified products may be altered according to the polymorphism to be detected.
• the nucleic acid probe sequence for use in the present invention is preferably a nucleic acid probe having a sequence containing a sequence selected from those in the fifth sequence group (Table 5) or a sequence complementary to a sequence selected from those in the fifth sequence group, or the sequence selected from those in the fifth sequence group or the sequence of the complementary to a sequence thereof of which one or more nucleotides are substituted, deleted or insertion. It is also possible to use ' the sequences described in Kleter et al., J. Clin. Microbiol., 37, 2508-17 (1999); Vernon et al., BMC Infectious Diseases, 3:12 (2003); JP-A 09-509062(KOKAI) and others. The structure of the nucleic acid probe is also not
• DNA, RNA, PNA, LNA, methyl phosphonate-skeleton nucleic acid, and other synthetic nucleic acid chains may also be used.
• the chimeric nucleic acids thereof may also be used.
• a functional group such as amino group, thiol group, or biotin, for immobilization of the nucleic acid probe on a solid support, and a spacer may also be introduced additionally between the functional group and the nucleotide.
• the kind of the spacer used herein is not particularly limited, and, for example, an alkane or ethylene glycol skeleton may be used.
• Examples of the universal nucleotides for use in the present invention include deoxyinosine (dl) and 3-Nitropyrrole, 5-Nitroindole, deoxyribofuramsyl (dP) , and deoxy-5 ' -dimethoxytrityl-D-ribofuranosyl (dK) available from Gren Research, and the like.
• the detection method for use in the invention is not particularly limited, and examples thereof include optical methods of using turbidity, visible light, fluorescence, chemiluminescence,
• ESR fluorescent energy transfer
• electrical methods of using an electrical ' property such as electrical current, voltage, frequency,
• the support for immobilizing the nucleic acid probe for use in the invention is not particularly limited, and examples thereof include particles (e.g., resin beads, magnetic beads, metal fine particles, and gold colloid), plates (e.g., microtiter plate, glass plate, silicon plate, resin plate, electrode plate, and membrane), and the like.
• particles e.g., resin beads, magnetic beads, metal fine particles, and gold colloid
• plates e.g., microtiter plate, glass plate, silicon plate, resin plate, electrode plate, and membrane
• the raw material for the support for use in the invention is not particularly limited, and examples thereof include permeable materials such as a porous material and membrane and non-permeable materials such as glass and resin.
• Typical examples of the support materials include inorganic insulation materials such as glass, quartz glass, alumina, sapphire, forsterite, silicon carbide, silicon oxide, and silicon nitride, and organic materials such as polyethylene, ethylene, polypropylene, polyisobutylene, polymethyl
• methacrylate polyethylene terephthalate, unsaturated polyesters, fluorine-containing resins, polyvinyl chloride, polychlorinated vinylidene, polyvinyl
• the support surface on which the nucleic acid chain is immobilized may be formed, for example, with an electrode material.
• the electrode material is not particularly limited, but examples thereof include pure metals such as gold, gold alloys, silver, platinum, mercury, nickel, palladium, silicon, germanium,
• the electrode can be produced by plating, printing, sputtering, vapor deposition, or the like.
• An electrode film may be formed in vapor deposition by resistance heating, high-frequency heating, or electron beam heating. When in sputtering, the electrode film may be formed by DC bipolar sputtering, bias
• photoresists for light irradiation examples include photoresists containing cyclized rubber, polycinnamic acid or novolak resin as the main raw material.
• a cyclized rubber, a phenol resin, polymethylisopropenylketone (PMIPK), polymethyl methacrylate (PMMA), or the like is used as the far- ultraviolet photoresist.
• PMIPK polymethylisopropenylketone
• PMMA polymethyl methacrylate
• Any one of COP, metal acrylate, as well as the substances described in the Thin Film Handbook (published by Ohmsha) may be used for the X-ray resist. Further, the substances
• the resist for use desirably has a thickness of IOOA or more and 1 mm or less. It is possible to make the area constant by covering the electrode with a photoresist and
• the resist material has been
• the resist material As a part of the electrode for gene detection without removal. In such a case, a substance higher in water resistance is needed to be used as the resist material.
• Materials other than the photoresist materials may be used for the insulation layer formed over the electrode. Examples thereof include oxides, nitrides, and carbides of metals such as Si, Ti, Al, Zn, Pb, Cd, W, Mo, Cr, Ta, and Ni and the alloys thereof.
• Electrodes units and immobilizing different probes thereon on a single chip It is also possible to test multiple samples at the same time by configuring several electrode units and immobilizing the same probe thereon on a single chip. In such a case, multiple electrodes are patterned on a substrate previously by photolithography. It is effective then to form an insulation film separating individual electrodes for prevention of contact of neighboring electrodes.
• the thickness of the insulation film is preferably about 0.1 to 100 micrometers.
• the sample to be analyzed in the present invention is not particularly limited, and examples thereof include blood, serum, leukocyte, urine, feces, semen, saliva, vaginal fluid, tissue, biopsy sample, oral mucosa, cultured cell, sputum, and the like.
• Nucleic acid components are extracted from these samples.
• the extracting method is not particularly limited, and examples thereof include liquid-liquid extraction, for example with phenol-chloroform, and solid-liquid extraction by using a carrier.
• Commercial nucleic acid-extracting kits such as QIAamp- (manufactured by QIAGEN), or Sumai test (manufactured by Sumitomo Metal Industries) may be used instead.
• the extracted nucleic acid components are amplified by LAMP methods, and the amplified product is hybridized with the probe
• the reaction is carried out in a buffer solution at an ionic strength in the range of 0.01 to 5 and at a pH in the range of 5 to 10.
• Other additives such as
• hybridization accelerator dextran sulfate, salmon sperm DNA, bovine thymic DNA, EDTA, and surfactant may be added to the solution.
• the amplified product is added thereto.
• hybridization may be performed by dropping the solution on the substrate.
• reaction may be accelerated, for example, by agitation or shaking during the reaction.
• the reaction temperature is preferably in the range of 10°C to 90°C, and the reaction period is about 1 minute or more to overnight.
• the electrode is separated and washed.
• a buffer solution at an ionic strength of 0.01 to 5 and a pH in the range of 5 to 10 is used for washing.
• the extracted nucleic acid sample can be detected, by labeling with a fluorescent dye such as FITC, Cy3, Cy5, or rhodamine; biotin, hapten, an enzyme such as oxidase or phosphatase, or an electrochemically active substance such as ferrocene or quinone, or by using a second probe previously labeled with the substance described above.
• a fluorescent dye such as FITC, Cy3, Cy5, or rhodamine
• biotin, hapten an enzyme such as oxidase or phosphatase, or an electrochemically active substance such as ferrocene or quinone
• nucleic acid components are analyzed in the following manner.
• a substrate is first cleaned, a DNA-binding substance selectively binding to the double-stranded region formed on the electrode surface is allowed to react, and the substrate is analyzed electrochemically.
• the DNA-binding substance for use is not particularly limited, and examples thereof include Hoechst 33258, acridine orange, quinacrine, daunomycin, metallointercalators, bisintercalators such as bisacridine, trisintercalators, and
• polyintercalators may be modified with an electrochemically active metallocomplex such as ferrocene or viologen.
• concentration of the DNA-binding substance may vary according to the kind thereof, but is generally in the range of 1 ng/ml to 1 mg/ml.
• a buffer solution at an ionic strength in the range of 0.001 to 5 and a pH in the range of 5 to 10 is used then.
• the electrode after reaction with the DNA-binding substance is washed and analyzed electrochemically .
• the electrochemical measurement is performed in a three-electrode analyzer including reference, counter, and action electrodes or in a two-electrode analyzer including counter and action electrodes.
• a voltage high enough to cause electrochemical reaction of the DNA- binding substance is applied, and the reaction current derived from the DNA-binding substance is determined.
• the voltage may be varied linearly, or may be applied in the pulse shape or at a constant voltage.
• the current and voltage during measurement are controlled by using a device such as a potentiostat, a digital multimeter, or a function generator.
• the concentration of the target gene is calculated from the measured electric current with a calibration curve.
• electrode includes a gene-extracting unit, a gene- reacting unit, a DNA-binding substance-reacting unit, an electrochemical measurement unit, a washing unit, and others.
• a method of diagnosing human papilloma viral infection comprising
• a step of amplifying the nucleic acid chains in the sample in LAMP reaction by. using multiple primers including at least one primer selected from the nucleic acid primers described above;
• a step of amplifying the nucleic acid chains in the sample in LAMP reaction by using multiple primers including at least one primer selected from the nucleic acid primers described above;
• the present invention provides a LAMP-amplification kit for use in the detection of human papilloma virus and identification of its genotype.
• the LAMP-amplification kit contains a nucleic acid primer selected from following (a)-(f) and additionally any other components needed for the LAMP amplification reaction such as polymerase, dNTPs, betaine, buffer, positive control DNA, and sterilized water:
• nucleic acid primer containing, on the same chain, a sequence complementary to a sequence selected from those in a first sequence group listed in Table 1 and a sequence selected from those in a second sequence group listed in Table 2 ;
• nucleic acid primer containing, on the same chain, a sequence complementary to a sequence selected from those in the first sequence group and a sequence selected from those in a third sequence group listed in Table 3;
• nucleic acid primer containing, on the same chain, a sequence complementary to a sequence selected from those in the second sequence group and a sequence selected from those in the third sequence group;
• nucleic acid primer containing a sequence that differs from a selected sequence of one of the nucleic acid primers (a), (b) , and (c), by insertion, deletion, or substitution of one or more bases, and capable to hybridize with a nucleic acid chain having a sequence complementary to the selected sequence of one of the nucleic acid primers (a), (b) , and (c);
• nucleic acid primer containing a sequence selected from those in a fourth sequence group listed in Table 4 or a sequence complementary thereto; and (f) a nucleic acid primer containing a sequence that differs from a selected sequence of one of the nucleic acid primers (e), by insertion, deletion, or substitution of one or more bases, and capable to hybridize with a nucleic acid chain having a sequence complementary to the selected sequence of one of the nucleic acid primers (e).
• the present invention provides a detection kit for use in the detection of human
• the detection kit includes the above-mentioned LAMP- amplification kit and a support carrying a nucleic acid chain immobilized thereon for detection of the human- papilloma-virus LAMP amplification products amplified by using the LAMP-amplification kit.
• the immobilized nucleic acid chain is;
• nucleic acid probe containing a sequence that differs from a selected sequence of one of the nucleic acid probe (g) , by insertion, deletion, or substitution of one or more bases, and capable to hybridize with a nucleic acid chain having a sequence complementary to the selected sequence of one of the nucleic acid probe (g) .
• the nucleic acid probe may be immobilized on the surface of a support, and the support and the support surface are made of the material described above.
• genotype is prepared in combination- of the sequences described in Table 1 above. More specifically, sequences in the first and the second sequence groups, sequences in the first and third sequence groups, or sequences complementary to the sequences in the second sequence groups and sequences in third sequence groups are bound to each other directly or via a spacer.
• a sequence in the fourth sequence group or a sequence complementary thereto is prepared. Any method known to those skilled in the art may be used in preparing the primers.
• the LAMP reaction solution had the composition shown in the following Table ⁇ .
• the template used was a plasmid DNA containing cloned HPV16.
• nucleic acid primer for LAMP amplification reaction shown in the following Table 7 was used as the same time.
• the nucleic acid amplification is carried out at a temperature of 58 0 C for 1 hour.
• a sample added with sterilized water instead of the template is used as the negative control.
• Analysis of the amplified LAMP products by agarose gel electrophoresis reveals a ladder-shaped pattern characteristic to LAMP products.
• no amplification is observed with a sample containing no template DNA. It is thus possible to perform sequence-specific amplification of the papilloma virus by using a selected primer set.
• the DNA probes 1 - 5 were immobilized on the slide glass 6.
• the nucleic acid sequence of them is shown in Table 8-1.
• HPVs 16 to 31 were used as sequences specific to the subtypes of HPV, while the rDNA's as negative controls.
• Each probe was modified with an amino group at the terminal, and was immobilized on a carbodiimide- treated slide glass substrate by spotting the probe solution thereon. Finally, the substrate l was washed with ultrapure water and air-dried, to give a DNA chip. (5) Hybridization of LAMP products to nucleic acid probe
• the LAMP products amplified in (3) above were used as a nucleic acid sample.
• the DNA chip prepared in (4) was hybridized by dipping it into the LAMP product solution containing 2 x SSC salt added and leaving it therein at 35°C for 60 minutes. Subsequently, Cy5- labelled nucleic acid of SEQ ID No. 7 was added
• the DNA probes 7 - 11 were immobilized on the electrode 13 placed on the support 12.
• the nucleic acid sequence of them is shown in Table 8-2.
• Connection part 14 may be placed on the support 12.
• HPVs 16 to 31 are used as sequences specific to the subtypes of HPV, while the rDNA's as negative controls.
• Each probe is modified with an amino group at the terminal, and is immobilized on a gold electrode by spotting the probe solution thereon. Finally, the substrate is washed with ultrapure water and air-dried, to give a DNA chip.
• the DNA chip prepared in (7) is hybridized by dipping it into the LAMP product solution containing added 2 x SSC salt and leaving it therein at 35 0 C for 60 minutes.
• the electrode is dipped into a phosphate buffer solution containing a 50 ⁇ M intercalating agent Hoechst 33258 for 15 minutes, and the oxidative current response of the Hoechst 33258 molecule is determined. (9) Result
• Amplification according to a kind of template was performed by using the primer shown in Table 9. As a result, a ladder-shaped band characteristic to LAMP amplification was observed, and genotype-specific amplification was confirmed (FIG. 7). Then,
• Detection of LAMP multiamplification products 1 The amplification products shown in FIG. 8 were detected by using a current-detecting DNA chip carrying the probes of sequence numbers 605, 623, 635, 652, 683, 763, and 793 immobilized on the same chip.
• the probes are designed to react specifically with the nucleic acids of sequence numbers of 16, 18, 31, 33, 45, 58, and 68, respectively. Reaction of the sample amplified only by using the templates 16 and 18 resulted in increase in current only on the electrodes
• genotype- specific detection FIG. 9
• Primer sets of groups A to D shown in Table 10 were mixed respectively to give multiple primer sets.
• the amplification of a kind of template was performed by using the multiple primer sets.
• the amplification was performed at a template concentration of 10 ⁇ copies/reaction at 65 degrees for 2 hours. As a result, genotype-specific amplification was confirmed (FIG. 10) .
• the amplification products shown in FIG. 10 were detected by using a current-detecting DNA chip carrying the probes of SEQ ID No. 602, 623, 635, 647, 657, 681, 694, 750, 762, 774, and 793 immobilized on the same chip.
• the probes are designed to react specifically with the nucleic acids of sequence numbers of 16, 18, 31, 33, 35, 45, 51, 56, 58, 59, and 68, respectively. Reaction of the sample obtained by amplification by using each of the 11 kinds of templates resulted in increase in current only on the electrode corresponding to the template, indicating genotype specific detection of 11 kinds of genotypes.
• Primer sets of groups A to D shown in Table 11 were mixed respectively to give multiple primer sets.
• tube A contains primer sets with primers 16, 35, and 59;
• tube B contains a primer set with primers 18, 39, and 56;
• tube C contains a primer set with primers 45, 51, 58, and 68;
• tube D contains a primer set with primers 31, 33, and 52.
• tube E contained primers of SEQ ID Nos . 801, 802, 803, and 804 prepared for amplification of human ⁇ -globin gene
• a plasmid corresponding to each HPV type was used as the template, and the hybridization was performed at a concentration of 10- ⁇ copies/reaction at 63°C for 1.5 hours, which confirmed genotype-specific amplification.
• the amplification products above were detected by using a current-detecting DNA chip carrying the probes of SEQ ID Nos. 600, 623, 630, 641, 654, 673, 676, 699, 725, 750, 752, 771, and 783 on a single chip. These probes are designed to react specifically with the sequences of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68, respectively.
• the oligonucleotide of SEQ ID No. 813 as a probe for detecting /3 -globin gene was immobilized as the positive control of reaction, and the oligonucleotide of SEQ ID No. 814 was

Landscapes

• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Analytical Chemistry (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Molecular Biology (AREA)
• Physics & Mathematics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Virology (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Priority Applications (1)

Applications Claiming Priority (4)

Publications (1)

Family

ID=37903541

Family Applications (2)

Family Applications Before (1)

Country Status (5)

Families Citing this family (18)

Family Cites Families (9)

• 2006
  • 2006-12-08 EP EP09015797A patent/EP2192199B1/de active Active
  • 2006-12-08 CN CN200680046297.9A patent/CN101326293B/zh active Active
  • 2006-12-08 WO PCT/JP2006/325010 patent/WO2007066831A2/en active Application Filing
  • 2006-12-08 JP JP2008528274A patent/JP4920686B2/ja active Active
  • 2006-12-08 KR KR1020117014993A patent/KR101192561B1/ko active IP Right Grant
  • 2006-12-08 KR KR1020117014994A patent/KR101192567B1/ko active IP Right Grant
  • 2006-12-08 KR KR1020087013741A patent/KR101063037B1/ko active IP Right Grant
  • 2006-12-08 CN CN201210013254.8A patent/CN102517401B/zh active Active
  • 2006-12-08 CN CN201210013281.5A patent/CN102586474B/zh active Active
  • 2006-12-08 EP EP06834753A patent/EP1957677A2/de not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events